CHRNA2 and cancer: After exclusion of genes at high risk of side effects upon inhibition in a PheWAS, cholinergic receptor nicotinic alpha 2 (CHRNA2), histamine receptor H3 (HRH3), and protein tyrosine kinase 6 (PTK6) were identified as potentially druggable targets.<h4>Conclusions</h4>In summary, we identified a shared genetic architecture comprising pleiotropic cerebellar hub genes linking PSU-cancer trait pairs and described potential interventional drugs.